My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Agile Therapeutics (AGRX)
AGRX nasdaq
United States
Agile Therapeutics

Agile Therapeutics Stock Analysis & Ratings

Agile Therapeutics Stock Analysis Overview

Smart Score
Learn more about TipRanks Smart Score
The Agile Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart


AGRX Stock Stats

Previous Close$0.6
Bid0.6101 x 20000
Ask0.63 x 7100
Today’s Range$0 - $0
52-Week Range$0.54 - $3.77
Average Volume1.61M
Market Cap$72.84M
P/E Ratio-0.8
Earnings DateMar 09, 2022

Company Description

Agile Therapeutics

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Drug Manufacturers
Alfred Altomari
101 Poor Farm Road, Princeton, NJ, 08540, US


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


What was Agile Therapeutics’s price range in the past 12 months?
Agile Therapeutics lowest stock price was $0.54 and its highest was $3.77 in the past 12 months.
    What is Agile Therapeutics’s market cap?
    Agile Therapeutics’s market cap is $72.84M.
      What is Agile Therapeutics’s price target?
      The average price target for Agile Therapeutics is $2.83. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $4.00 ,the lowest forecast is $2.00. The average price target represents 371.67% Increase from the current price of $0.6.
        What do analysts say about Agile Therapeutics?
        Agile Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is Agile Therapeutics’s upcoming earnings report date?
          Agile Therapeutics’s upcoming earnings report date is Mar 09, 2022 which is in 96 days.
            How were Agile Therapeutics’s earnings last quarter?
            Agile Therapeutics released its earnings results on Nov 02, 2021. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.192 by $0.012.
              Is Agile Therapeutics overvalued?
              According to Wall Street analysts Agile Therapeutics’s price is currently Undervalued.
                Does Agile Therapeutics pay dividends?
                Agile Therapeutics does not currently pay dividends.
                What is Agile Therapeutics’s EPS estimate?
                Agile Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Agile Therapeutics have?
                Agile Therapeutics has 121,400,000 shares outstanding.
                  What happened to Agile Therapeutics’s price movement after its last earnings report?
                  Agile Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.192. Following the earnings report the stock price went down -2.439%.
                    Which hedge fund is a major shareholder of Agile Therapeutics?
                    Among the largest hedge funds holding Agile Therapeutics’s share is Perceptive Advisors LLC. It holds Agile Therapeutics’s shares valued at 15M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis